Vemlidy’s price 4.7% ↓...Vemliver’s voluntarily 12.6% ↓
By Kim, Jung-Ju | translator Kim, Jung-Ju
23.05.22 05:50:04
가나다라
0
Price of 2 items whose PVA term expired will be cut from the 1st of next month
Companies opt to reduce the price by a single-digit rate for each strength of their baraclude product
Gilead’s adult chronic hepatitis B treatment, ‘Vemlidi Tab (tenofovir ala fenamide) will be subject to Price-Volume Agreement price cuts and be sold at a 4.7% lower price starting next month.
Daewoong Pharmaceutical opted to reduce the price of its latecomer Vemliver Tab by 12.6%.
According to industry sources on the 21st, the Ministry of Health and Welfare (MOHW) ‘Amendment to the drug reimbursement list and reimbursement ceiling price table’ contains the abovementioned changes that will become effective as of the 1st of next month.
◆Price cut for PVA drugs = The PVA price cut will be applied to two products next month, and the two drugs underwent PVA n
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)